• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

SynergEyes launches interactive Web site

Article

Carlsbad, CA?SynergEyes Inc. has launched its interactive Web site at www.synergeyes.com. The site offers the ophthalmic industry and the general public the opportunity to obtain product information for the hybrid contact lenses produced by the company. SynergEyes lenses feature a rigid, gas-permeable center and a soft, hydrophilic outer skirt, resulting in a durable hybrid lens for patients seeking crisp, clear vision with the comfort of a soft lens.

Carlsbad, CA-SynergEyes Inc. has launched its interactive Web site at http://www.synergeyes.com/. The site offers the ophthalmic industry and the general public the opportunity to obtain product information for the hybrid contact lenses produced by the company. SynergEyes lenses feature a rigid, gas-permeable center and a soft, hydrophilic outer skirt, resulting in a durable hybrid lens for patients seeking crisp, clear vision with the comfort of a soft lens.

"This new Web site provides easy navigation for practitioners seeking product information, including parameters, lens specifications, fitting techniques, and case studies, as well as a resource page for additional data," said Mary Loranger, vice president, Marketing, SynergEyes.

"SynergEyes now offers practitioners the opportunity to order lenses on-line, and to contact consultation via our Web site," she added.

SynergEyes M, a multifocal design with market clearance for presbyopia, is anticipated for release in April 2006. SynergEyes PS, designed for post surgical and post trauma, is pending FDA market clearance.

Related Videos
John Saharek, president of ImprimisRX, speaks with Ophthalmology Times' David Hutton on three new products the company will be featuring during the American Academy of Ophthalmology's 2021 annual meeting
What keeps you up at night in ophthalmology: Part II
Chris Adams, Diopter Corp CEO
Ramin Valian, of Allergan, discusses pharmaceuticals in the glaucoma industry at Glaucoma 360
© 2024 MJH Life Sciences

All rights reserved.